Temsirolimus efficacy

In advanced renal cell carcinoma, a major study involving 626 patients with a poor prognosis found that temsirolimus was more effective than interferon alfa, another drug used to treat cancer, in extending patients' survival. Patients received 25 mg of temsirolimus, interferon alfa, or 15 mg of temsirolimus combined with interferon alfa. Patients who received temsirolimus alone lived an average of 10.9 months, and those who received a lower dose of temsirolimus plus interferon alfa lived for 8.4 months.

In mantle cell lymphoma, temsirolimus was found to be more effective than alternative cancer drugs, such as gemcitabine or fludarabine, in a major study involving 162 patients whose disease had recurred after previous treatment or who had failed other treatments. Each patient received two doses of temsirolimus or the investigator's choice of the most appropriate alternative cancer drug. The main measure of effectiveness is how long patients live without their disease getting worse. Patients who received temsirolimus lived an average of 4.8 months without disease progression.

The original drug temsirolimus has not yet been marketed in China, and therefore cannot be included in domestic medical insurance. The original temsirolimus drug marketed overseas has a Turkish version and a European version. The ingredients of the two are basically the same. The price of each box of 30mg/1.2mL may be more than 10,000 yuan, and the price of 25mg/mL may be around 3,000 yuan per box (the price may fluctuate due to exchange rates). There is currently no generic version of temsirolimus available on the market. For more drug information and specific prices, please consult a medical consultant.